Clinical trial
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With…
NCT00042939 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00042939 |
|---|---|
| Title | Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | Phase II Trial of Irinotecan/Docetaxel for Advanced Pancreatic Cancer, With Randomization Between Irinotecan/Docetaxel and Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor (EGF-r) |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, docetaxel, irinotecan hydrochloride |
| Enrollment | 94 |
| Start date | Dec 9, 2003 |
| Primary completion | Jun 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 6, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: